Last reviewed · How we verify
Fexofenadine Tablets 180 mg
At a glance
| Generic name | Fexofenadine Tablets 180 mg |
|---|---|
| Sponsor | Mylan Pharmaceuticals Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Oedema mucosal
- Headache
- Nasal obstruction
- Seasonal allergy
- Skin abrasion
- Arthralgia
- Back pain
- Neck pain
- Sinus headache
- Nasal oedema
- Tinnitus
- Gastroenteritis
Key clinical trials
- A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis (PHASE3)
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED) (PHASE4)
- Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177) (PHASE4)
- Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054) (PHASE4)
- Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg (PHASE1)
- Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg (PHASE1)
- Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants (PHASE3)
- Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fexofenadine Tablets 180 mg CI brief — competitive landscape report
- Fexofenadine Tablets 180 mg updates RSS · CI watch RSS
- Mylan Pharmaceuticals Inc portfolio CI